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Abstract
Background: The DNA damage checkpoint signalling cascade sense damaged DNA and coordinates cell cycle
arrest, DNA repair, and/or apoptosis. However, it is still not well understood how the signalling system differentiates
between different kinds of DNA damage. N-nitroso-N-ethylurea (NEU), a DNA ethylating agent induces both
transversions and transition mutations.
Methods: Immunoblot and comet assays were performed to detect DNA breaks and activation of the canonical
checkpoint signalling kinases following NEU damage upto 2 hours. To investigate whether mismatch repair played a
role in checkpoint activation, knock-down studies were performed while flow cytometry analysis was done to
understand whether the activation of the checkpoint kinases was cell cycle phase specific. Finally, breast epithelial
cells were grown as 3-dimensional spheroid cultures to study whether NEU can induce upregulation of vimentin
as well as disrupt cell polarity of the breast acini, thus causing transformation of epithelial cells in culture.
Results: We report a novel finding that NEU causes activation of major checkpoint signalling kinases, Chk1 and Chk2.
This activation is temporally controlled with Chk2 activation preceding Chk1 phosphorylation, and absence of cross
talk between the two parallel signalling pathways, ATM and ATR. Damage caused by NEU leads to the temporal
formation of both double strand and single strand breaks. Activation of checkpoints following NEU damage is cell
cycle phase dependent wherein Chk2 is primarily activated during G2-M phase whilst in S phase, there is immediate
Chk1 phosphorylation and delayed Chk2 response. Surprisingly, the mismatch repair system does not play a role in
checkpoint activation, at doses and duration of NEU used in the experiments. Interestingly, NEU caused disruption of
the well-formed polarised spheroid archithecture and upregulation of vimentin in three-dimensional breast acini
cultures of non-malignant breast epithelial cells upon NEU treatment indicating NEU to have the potential to
cause early transformation in the cells.
Conclusion: NEU causes damage in mammalian cells in the form of double strand and single strand breaks that
temporally activate the major checkpoint signalling kinases without the occurrence of cross-talk between the pathways.
NEU also appear to cause transformation in three-dimensional spheroid cultures.
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Background
Alkylating agents are a structurally diverse group of
DNA damaging compounds which form adducts at ring
nitrogen (N) and extracyclic oxygen (O) atoms of DNA
bases [1]. N-nitroso-N-ethylurea (NEU), a simple mono-
functional SN1 type-DNA ethylating agent, forms the
modified base O6-ethylguanine (O6EtG) which mispairs
with thymine during DNA replication and thus primarily
induces A:T to T:A transversions or A:T to G:C transi-
tion mutations [2,3]. NEU has been traditionally charac-
terised as a severely potent transplacental teratogen and
carcinogen in rodents [4,5]. In vertebrates, the mismatch
repair proteins, namely Msh2-Msh6 and Mlh1-Pms2
heterodimers, play a pivotal role in mediating the muta-
genic and cytotoxic effects of O6EtG lesions [6,7]; how-
ever the mechanisms are still controversial. According to
one model, futile cycles of mismatch repair-induced
excision and repair of erroneously paired thymine nucle-
otides opposite O6EtG lesions cause formation of recur-
ring single strand breaks (SSBs). These gaps in the
genome and double strand breaks (DSBs) that form at
these sites during the next replication cycle have been
proposed to be mediating the cytotoxic effects of differ-
ent alkylating agents [8]. However according to an alter-
nate model, recognition of O6EtG:T mispairs by the
mismatch repair proteins can directly recruit DNA dam-
age response kinases at the site of DNA damage which
possibly elicits cell cycle checkpoint activation and apop-
tosis [9]. Interestingly, at high doses, cytotoxicity of SN1
type-alkylating agents has been shown to be largely
mismatch repair independent [10]. Hence the cellular
pathways that collectively modulate sensitivity to DNA
alkylation damage involve direct crosstalk, overlap in
substrates and recruitment of alternative pathways for
processing of intermediates.
The pathways that sense damaged DNA and coordin-
ate DNA repair, cell cycle arrest and/or apoptosis com-
prise the DNA damage checkpoint signalling cascade.
The sensor or apical kinases that detect the damaged
DNA belong to the phosphoinositide 3-kinase related
kinase (PIKK) family. These kinases, namely ATM (ataxia-
telangiectasia mutated) and ATR (ATM and Rad3-related),
initiate a cascade of phosphorylation events which mediate
cell cycle arrest, DNA repair and apoptosis [11]. The in-
creased local concentration of ATM at the DSB sites is
important to boost phosphorylation of ATM targets, in-
cluding signal mediators such as the Chk2 kinase [12].
ATR responds primarily to stalled replication forks, base
adducts and DNA cross-links, and relays the signal by
phosphorylating Chk1 kinase and a large subset of ATM
substrates [13]. However this paradigm of ATM and
ATR signalling through two independent and alternate
pathways was recently challenged and redefined by sev-
eral reports showing that ATR can be activated directly
in response to DSBs specifically in S and G2 phases of the
cell cycle [14,15]. Recruitment of ATR to ionising radi-
ation (IR)-induced DSBs occurs in an ATM and Mre11-
Rad50-Nbs1 (MRN) complex-dependent manner at time
points following ATM activation [16]. Though DNA alkyl-
ating agents do not directly induce strand breaks, low
doses of SN1 type-methylating agents have been shown to
induce activation of the apical kinases, ATM and ATR,
and their downstream substrates [10,17]. Most studies
suggest that checkpoint activation can occur only in the
second G2 phase after DNA alkylation damage, however
few findings have reported ATM activation within 3 hrs of
treatment with a prototypical SN1 type-methylating agent
[18]. Furthermore, SSBs have been shown to accumulate
as primary lesions in cells after 2 hrs of NEU damage [19].
These findings, being contrary to the standard model of
DNA alkylation damage, have led to the possibility that
SN1 type-alkylating agents can induce strand breaks in a
replication-independent manner.
Loss of cellular architechture and polarity of breast
tissue is one of the early markers for onset of breast
cancer. This loss in cellular morphology can be phenocop-
ied using three-dimensional (3D) cultures of human mam-
mary epithelial cells, MCF10A. MCF10A are immortalised,
non-transformed human mammary epithelial cells when
grown in 3D matrices, exhibit a number of features of nor-
mal breast epithelium [20]. MCF10A cells form multicellu-
lar acini-like spheroids which represent the layer of basal
epithelial cells surrounding a hollow lumen in the lobule of
human mammary gland [21]. The morphology of these
acini are disrupted in malignancy, such as an increase in
size and elongation of acini [22]. As transformation pro-
gresses, the acini lose their polarisation and some may even
form multi-acinar structures [21]. Another characteristic of
transformed cells is their ability to invade and metastasise
to the other tissues. During the process of transform-
ation the epithelial cells are said to undergo ‘epithelial -
mesenchymal’ (EMT) transition [23-25].
In this study, we have investigated the activation of
DNA damage response kinases in human cancer cell
lines following 2 hours treatment with different doses of
NEU. Mismatch repair-proficient and mismatch repair-
deficient cells were used to address the dependence on
an active mismatch repair system for signalling to apical
kinases of the DNA damage response signalling cascade
after ethylation damage. We also explored the possibility
of crosstalk and/or interdependence between the two ca-
nonical DNA damage response pathways, namely ATM
through Chk2 and ATR through Chk1, post-NEU treat-
ment for 2 hours. The data indicate presence of a mis-
match repair-independent and cell cycle phase-dependent
mechanism of checkpoint activation in mammalian cells
immediately after treatment with a prototypical SN1 type-
ethylating agent. Using the 3D platform to investigate
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whether NEU has the potential to cause transformation of
breast epithelial cells grown as spheroids, it was observed
that upon NEU treatment to MCF10A acinar cultures, the
well organised polarised structures were completely dis-
trupted upon transformation. Vimentin, an EMT marker
was also observed in the NEU-treated breast acini, thereby
indicating NEU to cause an EMT-like phenotype in the
transformed breast epithelial cells grown in 3D.
Methods
Cell lines and culture conditions
MCF7 cell line was purchased from European Collection
of Cell Cultures (ECACC). HeLa and HCT 116 cell lines
were generous gifts from Dr. Sorab Dalal (ACTREC,
Mumbai, India). DLD1 cell line was a kind gift from
Dr. Thomas Ried (NCI, NIH, USA). MCF10A cell line
was a generous gift from Prof. Raymond C. Stevens (The
Scripps Research Institute, California, USA). All cell lines
were grown in High Glucose Dulbecco’s Modified Eagle
Medium (DMEM; Invitrogen or Lonza) containing 10%
fetal bovine serum (FBS; Invitrogen), 2 mM L-glutamine
(Invitrogen) and 100 units/mL penicillin-streptomycin
(Invitrogen). MCF10A cells were grown in High Glucose
DMEM without sodium pyruvate (Invitrogen) con-
taining 5% horse serum (Invitrogen), 20 ng/mL EGF
(Sigma), 0.5 μg/mL hydrocortisone (Sigma), 100 ng/mL
cholera toxin (Sigma), 10 μg/mL insulin (Sigma) and
100 units/mL penicillin-streptomycin (Invitrogen) and
were resuspended during sub-culturing in High Glu-
cose DMEM without sodium pyruvate containing 20%
horse serum and 100 units/mL penicillin-streptomycin
(Invitrogen). Cells were maintained in 100 mm tissue-
culture treated dishes (Corning) at 37°C in humidified 5%
CO2 incubator (Thermo Scientific).
Chemicals and antibodies
Dimethyl sulfoxide (DMSO), N-nitroso-N-ethylurea (NEU),
neocarzinostatin (NCS), thiazolyl blue tetrazolium brom-
ide (MTT), thymidine, nocodazole, RNase A and propi-
dium iodide (PI) were purchased from Sigma-Aldrich.
Selective ATM inhibitor KU 55933 and DNA-PK inhibitor
DMNB were obtained from Tocris Bioscience. VE 821, a
potent and selective ATR kinase inhibitor was purchased
from Axon Medichem. Monoclonal antibodies for Chk1
and Msh2 were bought from Santa Cruz Biotechnology.
Polyclonal antibodies for phospho-Chk1 (Ser345), phospho-
Chk2 (Thr68) and monoclonal antibodies for Chk2 and
RPA32 were purchased from Cell Signaling Technology.
Polyclonal antibody for phospho-RPA (Thr21) and mono-
clonal antibodies for phospho-ATM (Ser1981) and ATM
were obtained from Abcam. Monoclonal antibodies for
γH2AX (Ser139) and α6 integrin were bought from
Millipore while α-tubulin was from Sigma. Monoclonal
antibodies for vimentin, E-cadherin and β-catenin were
purchased from Abcam. Peroxidase-conjugated AffiniPure
goat anti-mouse, anti-rabbit and anti-rat IgG (H+ L) as
well as AffiniPure F(ab’)2 fragment goat anti-mouse IgG,
F(ab’)2 fragment specific were obtained from Jackson
Immuno Research. 4′, 6-Diamidino-2-phenylindole dihy-
drochloride (DAPI), Alexa Fluor 488 donkey anti-rabbit
IgG (H+ L) and Alexa Fluor 568 goat anti-mouse IgG
(H + L) were bought from Invitrogen.
MTT-based cytotoxicity assay
Cells were seeded at a density of 104 cells per well in 96-
well flat bottom tissue culture treated plates (Corning)
and maintained at 37°C for 16 hours. Cells were then
treated with NEU for 2 hours. Medium containing drug
was aspirated and fresh growth medium containing
0.5 mg/mL MTT was added to cells. Plates were main-
tained in dark at 37°C for 4 hours. Medium-MTT mixture
was aspirated and MTT-formazan crystals were dissolved
in DMSO. Plates were kept on a nutating shaker at room
temperature (RT) for 5 minutes and absorbance was re-
corded at 570 nm using a Varioskan Flash Multimode Plate
Reader (Thermo Scientific).
Drug treatment and time course assays
Cells were seeded at a density of 106 cells per well in
6-well tissue culture treated plates (Corning) and main-
tained at 37°C for 16 hours. Cells were then treated with
NEU by direct addition of drug to the culture medium
for 2 hours (unless otherwise indicated). Control cells
were treated with equivalent volume of DMSO (drug
solvent). For ATM and DNA-PK inhibition, cells were
treated with 10 μM KU 55933 and 25 μM DMNB, respect-
ively, immediately prior to addition of drug while for ATR
inhibition 10 μM VE 821 was added one hour prior to
addition of NEU to the cells. For time course studies, cells
were treated with NEU for different time periods ranging
from 0 to 120 minutes. After drug treatment, medium con-
taining NEU was aspirated and cells were washed once
with 1X phosphate buffered saline (PBS; PAN-Biotech
GmbH). Cells were lysed in sample buffer containing
0.06 mM Tris (pH 6.8), 6% glycerol, 2% sodium dodecyl
sulphate (SDS), 0.1 M dithiothreitol (DTT) and 0.006%
bromophenol blue and lysates were stored at - 40°C.
Single cell gel electrophoresis (Comet assay)
DNA strand breaks were detected using single cell gel
electrophoresis/comet assay, using standard protocols
[26]. Comet slides were then stained with ethidium brom-
ide at a concentration of 2 μg/ml for 5 minutes and then
were scored for comets immediately. Images were acquired
using epiflourescence microscope at 20X magnification.
Randomly selected 50 cells were analysed per sample.
Amount of DNA SSBs and DSBs were measured and rep-
resented as length of tail and relative DNA content in tail.
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siRNA knockdown
siRNA duplexes targeting Msh2, Msh6 and LacZ were
purchased from Dharmacon (Thermo Scientific). Sense
sequences of the siRNA are: Msh2, 5′-ACAGAAUA
GAGGAGAGAUUUU-3′; Msh6, 5′-GAAUACGAGUU
GAAAUCUAdTdT-3′; LacZ, 5′-CGUACGCGGAAUA
CUUCGAdTdT-3′. HeLa cells were seeded at a density
of 0.3 X 105 cells per well in 12-well tissue culture
treated plates (Corning) and maintained at 37°C for
24 hours. Transfections were performed with a final
siRNA concentration of 100 nM using X-tremeGENE
siRNA transfection reagent (Roche) diluted in Opti-
MEM I Reduced Serum Medium (Invitrogen). DMEM
supplemented with 30% FBS was added 4 hours post-
transfection to achieve a final FBS concentration of
10% in the wells. After 24 hours, siRNA transfection
was repeated for each set. Cells were maintained at
37°C for an additional 48 hours and NEU damage was
induced before lysis using same procedure as described
earlier.
Immunoblot analysis
Cell lysates were resolved using sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to Immobilon-P polyvinylidene difluoride
(PVDF) membrane (Millipore). Blocking was performed
in 5% (w/v) skimmed milk (SACO Foods, USA) for
non-phospho antibodies or 4% (w/v) Block Ace (AbD
Serotec) for phospho-specific antibodies prepared in
1X tris buffered saline containing 0.1% Tween 20 (1X
TBS-T) for 1 hour at RT. Blots were incubated for
3 hours at RT (or for 16 hours at 4°C) in primary anti-
body solution. Following washes, blots were incubated
with peroxidase-conjugated secondary antibody solu-
tion prepared in 5% (w/v) skimmed milk in 1X TBS-T
for 1 hour at RT following which blots were devel-
oped using Immobilon Western Detection Reagent kit
(Millipore) and visualised using ImageQuant LAS 4000
(GE Healthcare). All western data were quantified using
minimum three independent experiments and have been
denoted as fold-difference over respective controls for
each blot.
Cell cycle synchronisation
Cell cycle synchronisation for S (double thymidine block)
and G2 (thymidine-nocodazole block) phases were per-
formed following the protocol mentioned by Whitfield
et al. [27]. For the S phase synchronisation, HeLa cells were
seeded at a density of 105 cells per well in 6-well tissue-
culture treated plates while for synchronisation in G2
phase, cells were seeded at 2.5 X 105 cells per well in
6-well tissue-culture treated plates. The cells were released
into DMEM containing 10 mM NEU and harvested at dif-
ferent time points.
Cell cycle analysis
HeLa cells were synchronised as mentioned above and
harvested by trypsinisation. Cells were washed twice
with 1X PBS and fixed with 70% ethanol at least over-
night at 4°C. Cells were then washed twice with 1X
PBS, resuspended in a solution containing 20 mg/ml
RNase A and 1 mg/ml PI and incubated at 37°C for
1 hr. Cell cycle analysis was performed using FACS-
Calibur flow cytometer (BD Biosciences) and data was
analysed using ModFit (Verity Software House, Topsham,
ME, USA).
Immunofluorescence analysis
Cells were seeded at a density of 2 X 105 cells per well
on top of glass cover slips (Micro-Aid, India). Follow-
ing drug treatment, cells were fixed using 4% formalin
(Macron Chemicals) and were permeabilised using 0.5%
Triton-X-100 for 5 minutes at RT. Cells were blocked with
10% (v/v) goat serum (Abcam), stained with primary anti-
body and then incubated with secondary antibody. For
FITC-conjugated γH2AX (Ser139), the secondary antibody
step was skipped. Cells were then counterstained with
0.5 μg/ml DAPI and mounted on glass slides (Micro-Aid,
India). Slides were visualised under an Axio Imager.Z1
ApoTome microscope or a LSM 710 laser scanning con-
focal microscope (Carl Zeiss, GmbH). All microscopy im-
ages, unless otherwise specified, were captured using 63X
oil-immersion objective.
3D “on-top” culture
The 3D on top cultures were set up in 8-well chamber
coverglass (Nunc Lab tek, Thermo Scientific) using proto-
col described previously [21,28]. Cells were seeded at a
density of 0.5 X 104 cells per well. Cultures were main-
tained for 20 days and medium was supplemented every
4 days [21]. For drug treatments, NEU was directly added
to the culture medium on day 0 and 2. (Day 0 being the
day of seeding).
In-well 3D culture extraction and immunofluorescence
The acini were fixed on the 20th day using 4% parafor-
maldehyde (PFA) (freshly prepared in PBS, pH 7.4), per-
meabilised using PBS containing 0.5% Triton-X-100 for
10 minutes at 4°C, and immunostaining was done using
standard protocols [21,28]. 3D structures were visualised
under a Zeiss LSM 710 laser scanning confocal micro-
scope (Zeiss, GmbH). All immunofluorescence images,
unless otherwise specified, were captured using 63X oil-
immersion objective.
Statistical analysis
Data represented in comet assay graphs are mean +/−
standard error of parameters recorded from three inde-
pendent experiments. Student’s t-test was used to analyse
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the statistical significance of fold-difference between
treated and control samples in the western blots. Student’s
t-test was also used to analyse the statistical significance of
difference in tail length. The results for % DNA in tail were
analysed using nonparametric test one-tailed Mann
Whitney U test. One way ANOVA was used to analyse
the statistical significance of difference in the relative
DNA content in tail for time course experiments. The
results for % DNA in tail were also confirmed using
nonparametric tests (Kruskal-Wallis test). The data was
analysed using GraphPad Prism software (GraphPad
Software, La Jolla, CA, USA), and p < 0.05 has been consid-
ered as significantly different.
Results
NEU damage activates DNA damage response kinases
To evaluate the cytotoxicity induced by NEU in MCF7
(breast adenocarcinoma origin) and HeLa (cervical
adenocarcinoma origin) cell lines, MTT-based cell via-
bility assay was used (see Additional file 1: Figure S1, A
and B respectively). In the dose range at which cell
viability was between 50% and 100%, NEU induced
phosphorylation of the DNA damage response kinases
ATM, Chk2 and Chk1 was observed in MCF7 and
HeLa cells in a dose dependent manner (Figure 1A and
Additional file 1: Figure S1C). To investigate whether
DNA damage cascades are activated on exposure to
NEU doses at which cell viability is higher than 70%,
we treated MCF7 and HeLa cells with drug concentra-
tions lower than 2 mM. Interestingly, phosphorylation
of ATM, Chk2 and Chk1 were also detected in the low
dose range of NEU (Figure 1B and Additional file 1:
Figure S1D). Since both DSB and SSB response path-
ways were activated after exposure to NEU, we sought
to visualise the presence of these breaks immediately
after NEU damage. γH2AX foci formation was ob-
served in HeLa and MCF7 cells after 1 hour of NEU
damage and these nuclear foci intensified with increase
in concentration of the drug (Figure 1C and Additional
file 1: Figure S1E). NEU damage also led to phosphoryl-
ation of RPA at threonine 21 residue and induced local-
isation of phospho-RPA proteins to nuclear foci in HeLa
cells within 2 hour of addition of the drug (Figure 1D
and E). Neutral and alkaline comet assays were per-
formed to further confirm the formation of DSBs and
SSBs respectively. A significant increase in comet for-
mation was observed in MCF7 cells post NEU dam-
age for 2 hours (Figure 1F and G; Additional file 2:
Figure S2A and B) compared to control cells. Together
these data suggests that NEU induces formation of
both SSBs and DSBs within two hours, which leads to
the activation of the DNA damage response signalling
cascades, namely Chk1 and Chk2 with formation of
damage-induced foci.
NEU-induced DNA damage response activation is
independent of the mismatch repair system
Earlier reports have shown mismatch repair proteins to
mediate checkpoint activation and downstream cytotoxic
effects induced upon exposure to DNA alkylating agents
[10,17,29,30]. To investigate whether activation of DNA
damage response after NEU damage was dependent on
mismatch repair, we performed individual knockdowns of
the mammalian MutS homologs, Msh2 and Msh6, in HeLa
cells. Knocking down of Msh2 or Msh6 using siRNAs
against the endogenous proteins did not affect the check-
point response following 2 hours of NEU treatment
(Figure 2A). Phosphorylation of Chk1 at serine 345 and of
Chk2 at threonine 68 was observed in Msh2 or Msh6
knocked down cells following NEU damage. The levels of
phospho-Chk1 (Ser 345) in NEU-treated Msh2 or Msh6
RNAi-depleted cells were simlar to that of LacZ RNAi
knocked down cells in the presence of NEU (1.3 fold for
Msh2 and Msh6 siRNA lanes compared to LacZ control in
the presence of damage). Similarly the levels of Chk2 phos-
phorylation in Msh2 or Msh6 RNAi-depleted cells fol-
lowing NEU damage were 1 and 0.7 fold difference in
comparison to NEU damaged LacZ lane and hence the ac-
tivation of both Chk1 and Chk2 remain unperturbed in
NEU-treated Msh2 or Msh6 RNAi-depleted cells. To fur-
ther explore DNA damage response activation after NEU
damage mismatch repair-deficient cell lines, HCT 116, a
MLH1 deficient cell line of colon cancer origin and DLD1,
a MSH6 deficient (frame-shift mutation in Msh6) cell line
derived from colorectal adenocarcinoma were used in the
experiments. In HCT 116, activation of the DNA damage
response kinases ATM, Chk2 and Chk1 were observed after
exposure to NEU concentrations from 2 mM to 10 mM for
2 hours (Figure 2B). Similar results were obtained for
DLD1 cells (Figure 2C). Though it has been previously re-
ported that the DLD1 cell line is Chk2 deficient [31], we
could detect low amounts of phosphorylation of Chk2 at
threonine 68 position in DLD1 cells which was reduced in
presence of an ATM autophosphorylation inhibitor, KU
55933 (Figure 2D). To confirm that DNA damage response
activation in mismatch repair-deficient cells occurs due to
formation of breaks in the genome after NEU damage, we
investigated the formation of γH2AX foci in DLD1 cells
after exposure to NEU (Figure 2E). We observed that simi-
lar to mismatch repair-proficient cells, γH2AX foci were
prevalent in DLD1 cells after 1 hour of NEU damage. These
results collectively suggest that activation of DNA damage
cascades after exposure to the SN1 type-ethylating agent
NEU for 2 hours is largely mismatch repair-independent.
Activation of ATM-Chk2 checkpoint pathway precedes but
is not required for activation of ATR-Chk1 response pathway
Since we observed phosphorylation of ATM and Chk2
as well as that of Chk1 kinase after treatment of MCF7
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and HeLa cells for 2 hours with NEU, we investigated
the temporal sequence of activation of these two ca-
nonical DNA damage response pathways. On perform-
ing a time course assay in MCF7 and HeLa cells, we
could detect phosphorylation of ATM and Chk2 10
minutes after initial exposure to NEU while Chk1 phos-
phorylation was detected 20 minutes after drug damage
(Figures 3A and 4A). This pattern of checkpoint activa-
tion was similar to a previously reported ATM-to-ATR
switch that has been shown to be involved in resection
of DSBs [32]. To confirm our results regarding tem-
poral activation of DNA damage response pathways,
MCF7 cells treated with 10mM NEU for similar time
points were subjected to neutral and alkaline comet assay
(Figure 3B and Figure 3C). In the neutral comet assay
(Figure 3B and Additional file 2: Figure S2C), tails were
visible at 10 minutes post NEU damage. The comet tails
in the NEU-damaged cells were significantly longer with
higher percentage of DNA compared to the control cells.
In the alkaline comet assay, comet tails were observed 20
Figure 1 NEU causes activation of checkpoint signalling pathways in a dose dependent manner. (A) MCF7 cells were treated with 0, 2, 6
and 10 mM NEU for 2 hours and lysates were analysed for activation of checkpoint proteins by immunoblotting. (B) MCF7 cells were treated with
0, 0.3, 0.6, 1.2 and 1.8 mM NEU for 2 hours and lysates were analysed for activation of checkpoint proteins by immunoblotting. (C) HeLa cells
were treated with 0.3 and 10 mM NEU for 1 hour, fixed and analysed for γH2AX foci formation by immunostaining. DMSO was used as negative
control and neocarzinostatin (NCS), an IR-mimetic drug, was used as positive control at a concentration of 200 ng/ml. Scale bar: 20 μM. (D) HeLa
cells were treated with 0.3 and 10 mM NEU for 2 hours, fixed and analysed for pRPA foci formation by immunostaining. DMSO was used as
negative control. Scale bar: 20 μM. (E) HeLa cells were treated with 0, 0.3 and 10 mM NEU for 2 hours and lysates were analysed for phosphorylation
of RPA. (F and G) MCF7 cells treated with 0 and 10 mM NEU for 2 hours were collected, embedded in agarose and layered on slides. Cells were
subjected to lysis followed by electrophoresis in neutral and alkaline conditions respectively. N = 150 cells (50 cells/experiment). Data shown are
mean +/− standard error. The results for % DNA in tail and tail length are significantly different at p < 0.05 in Mann Whitney U test and student’s
t test respectively.
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minutes after NEU treatment (Figure 3C and Additional
file 2: Figure S2D). There was not much tail formation in
the 10 minute NEU-treated cells while the 20 minute
NEU-damaged cells showed a significant increase in tail
length and percentage tail DNA when compared to the
untreated cells. KU 55933, an inhibitor of ATM auto-
phosphorylation was used to investigate whether activa-
tion of upstream kinases in the DSB response pathway is
essential for activation of the SSB response kinase Chk1
after DNA damage. Interestingly, though ATM and Chk2
phosphorylation were almost completely diminished after
pre-treatment of MCF7 cells with KU 55933 prior to
NEU treatment, unlike the findings in the previous study
[32], Chk1 phosphorylation remained unhampered and
was observed in 10 mM NEU damaged MCF7 cells
treated with the ATM inhibitor (Figure 3D). DMNB, a
DNA-PK inhibitor, was used either separately or along
with KU 55933 in this experiment since members of the
PIKK family of kinases show functional redundancy in
ATM-deficient cells [33]. However DNA-PK inhibition did
not have any significant effect on the phosphorylation pro-
file of checkpoint proteins after NEU damage (Figure 3D).
To investigate whether inhibition of DSB response pathway
alters the temporal profile of Chk1 activation after treat-
ment with NEU, a time course assay was performed in
MCF7 cells pre-incubated with KU 55933. ATM and
Chk2 phosphorylation was totally abolished at all time
points in cells pre-treated with the ATM inhibitor
before addition of NEU. Interestingly, Chk1 phosphor-
ylation appeared at the same time point (20 minutes)
after NEU damage (2.9 fold difference over control)
as was observed in the absence of ATM inhibition
Figure 2 Checkpoint activation in response to NEU-induced damage is independent of mismatch repair. (A) siLacZ, siMsh2 and siMsh6
transfected HeLa cells were treated with 10 mM NEU for 2 hours and lysates were analysed for activation of checkpoint proteins by immunoblotting.
(B) HCT116, a MLH1-deficient cell line, was treated with 0, 2, 6 and 10 mM NEU for 2 hours and lysates were analysed for activation of checkpoint
proteins by immunoblotting. (C) DLD1, a MSH6 deficient cell line, was treated with 0, 2, 6 and 10 mM NEU for 2 hours and lysates were analysed
for activation of checkpoint proteins by immunoblotting. (D) DLD1 cells were treated with 10 mM NEU in presence of 10 μM KU 55933 (ATM inhibitor)
for 2 hours and lysates were analysed for activation of checkpoint proteins by immunoblotting. (E) DLD1 cells were treated with 10 mM NEU for 1 hour,
fixed and analysed for formation of γH2AX foci by immunostaining. DMSO was used as negative control and 200 ng/ml NCS, an IR-mimetic drug, was
used as positive control. Scale bar: 20 μM.
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(Figure 3E). To completely rule out cross-talk between
the two canonical signalling pathways, VE 821, a potent
ATP-competitive inhibitor of ATR [34] was added to cells
prior to NEU treatment and a time-course assay was per-
formed (Figure 3F). VE 821 compleletly abrogated Chk1
phosphorylation in cells damaged with NEU at all time
points. However, both Chk2 and ATM phosphorylation
was observed at 10 mins post NEU treatment (3.8 and
2.2 fold difference over control for pChk2 and pATM re-
spectively). In summary, these results point towards a
temporal delay in activation of the Chk1 kinase in com-
parison to that of ATM-Chk2 kinases after DNA damage
induced by NEU, however activation of both pathways
are independent of each other.
Figure 3 ATM and Chk2 activation precedes but is not required for Chk1 activation. (A) MCF7 cells were treated with 10 mM NEU for
different time intervals and lysates were analysed for activation of checkpoint proteins by immunoblotting. (B and C) MCF 7 cells treated with
10 mM NEU at different time points were used for analysing DNA DSBs (neutral comet assay) and SSBs (alkaline comet assay) respectively.
N = 150 cells (50 cells/experiment). Data shown are mean +/− standard error. The results for % DNA in tail and tail length are significantly different
at p < 0.05 in Mann Whitney U test and student’s t test respectively. (D) MCF7 cells were treated with 10 mM NEU in presence of 10 μM KU 55933
(ATM inhibitor) or 25 μM DMNB (DNA-PK inhibitor) or a combination of both for 2 hours and lysates were analysed for activation of checkpoint
proteins by immunoblotting. (E) MCF7 cells were treated with 10 mM NEU in presence of 10 μM KU 55933 for different time intervals and lysates
were analysed for activation of checkpoint proteins by immunoblotting. (F) MCF7 cells were treated with 10 mM NEU in presence of 10 μM VE 821
for different time intervals and lysates were analysed for activation of checkpoint proteins by immunoblotting.
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NEU-induced activation of SSB response pathway is cell
cycle phase dependent
Since the nature of DNA damage induced by alkylating
agents has been proposed to be dependent on replica-
tion of DNA at the damaged site [35,36], we compared
the temporal profile of checkpoint activation after NEU
damage in asynchronous and phase-synchronised HeLa
cell populations (Figure 4). In asynchronous HeLa cells,
ATM and Chk2 were phosphorylated after 10 minutes
of NEU damage while Chk1 phosphorylation was de-
tected after 20 minutes of initial exposure to the drug
(Figure 4A). Interestingly, Chk1 phosphorylation was
detected as early as 0 minutes after NEU damage in S
phase synchronised HeLa cells (Figure 4B). Also, these
cells showed a delayed activation of ATM and Chk2 fol-
lowing exposure to NEU (Figure 4B). In cells synchronised
in the G2-M phase, the temporal profile of ATM and Chk2
activation after NEU treatment was slightly delayed to that
in asynchronous cells (30 minutes instead of 20 minutes as
shown in Figure 4C. However NEU did not induce activa-
tion of Chk1 even after 2 hours of treatment to G2-M
phase synchronised HeLa cells (Figure 4C). Collectively,
we conclude that the profile of NEU-induced activation of
ATM and Chk2 kinases was conserved across cell cycle
phases while the susceptibility to activation of Chk1 kinase
after DNA damage induced by NEU was highest in the S
phase and least in the G2-M phase. A temporal delay in ac-
tivation of ATM-Chk2 in S phase may be due to a delay in
formation of DSBs during that phase.
NEU disrupts cell polarity and induces upregulation of
vimentin in MCF10A acini grown in 3D matrices
NEU was shown to disrupt polarisation in MCF10A
breast epithelial cells grown as 3D ‘on top’ cultures.
MCF10A epithelial cells when grown on Matrigel® differ-
entiate to form polarised acinar structures with hollow
Figure 4 NEU-induced activation of DNA damage response pathway is cell cycle phase dependent. (A) HeLa cells were treated with
10 mM NEU for different time intervals and lysates were analysed for activation of checkpoint proteins by immunoblotting. (B) HeLa cells
synchronised in S phase using double thymidine block were treated with 10 mM NEU for different time intervals and lysates were analysed for
activation of checkpoint proteins by immunoblotting. (C) HeLa cells synchronised in G2 phase using thymidine-nocodazole block were treated
with 10 mM NEU for different time intervals and lysates were analysed for activation of checkpoint proteins by immunoblotting. (D) Cell cycle
profile of propidium iodide (PI) stained asynchronous, S phase synchronised and G2-M phase synchronised HeLa cells using Flow Cytometer.
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lumen attached to the basement membrane, as shown in
Figure 5A. On treatment with two doses of NEU (day 0
and 2), the polarisation appears to get disrupted, as seen
by the presence of α-6 integrin on the baso-lateral and
apical regions, rather than its strong basal and weak
lateral localisation. Also, a few acini showed loss of in-
tegrin in certain regions ( as shown by white arrows in
Figure 5A). Similar loss has been observed in cells that
metastasise to the parenchyma and pleural cavity [37-39].
β-catenin was found to be disrupted and its presence was
seen in the cytoplasm rather than at the cell-cell junctions
(membraneous localisation). In addition to the disruption
of cell polarity, an upregulation of vimentin was observed
following NEU-treatment (Figure 5B). E-cadherin also
showed a marginal decrease (Figure 5C) indicating a reduc-
tion of this epithelial cell marker.
Discussion
Here, we report a novel finding that damage induced on
DNA by a prototypical SN1 type-ethylating agent, NEU
caused rapid activation of major kinases (ATM, Chk2
and Chk1) involved in the checkpoint signalling pathway
as well as has the potential to cause transformation in
breast acini grown as 3D cultures. The activation of the
kinases is cell cycle phase dependent and is temporally
controlled without any cross talk between the two paral-
lel signalling pathways, ATM and ATR. Interestingly,
mismatch repair system does not seem to play a role at
the doses of NEU used in the experiments and the time
of exposure of the cells to the chemical agent.
Activation of both Chk1 and Chk2, which are the two
major signal relay proteins in the checkpoint signalling
cascade and ATM, an apical sensor kinase, were ob-
served in the presence of increasing dose of NEU. Acti-
vation of the above-mentioned kinases following NEU
damage is indicative of lesions, both DSBs and SSBs be-
ing formed on DNA. This is interesting since within a
short time interval of NEU damage, there is an immedi-
ate checkpoint response which is in contrast to earlier
studies where alkylation damage forms detectable lesions
Figure 5 NEU induces upregulation of vimentin and disrupts polarity in MCF10A breast acini. MCF10A cells were grown as 3D ‘on top’
cultures in Matrigel™. 2, 3 and 5 mM NEU was administered on Day 0 and Day 2. The acini were cultured for 20 days and then immunostained
for (A) α6-integrin (green), β-catenin (red) and DAPI (blue) to stain nuclei (B) Vimentin (green) a marker for EMT and (C) E-cadherin (green). The
data is representative of 40 – 50 acini from three biologically independent experiments.
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following one to two cell division cycles (10). Neutral and
alkaline comet assays [19,40-42] as well as phosphoryl-
ation of γH2AX on serine 139 and phosphorylation of
RPA on threonine 21 confirmed the presence of breaks,
both double and single stranded following 2 hours of NEU
damage to cells.
Activation of the DNA damage checkpoint pathway is
thought to involve the independent recruitment and
localisation of the ATM-Chk2 and ATR-Chk1 pathways
[11-13]. Challenging this notion, recent reports have
shown the existence of considerable cross talk between
the two pathways [14,43]. Our data showed the activa-
tion of both ATM-Chk2 and ATR-Chk1 pathways in a
temporal manner with activation of ATM-Chk2 and
Chk1 kinases at 10 minutes and 20 minutes respectively
after addition of NEU for 2 hours to the cells (as depicted
in Figure 6). This pattern of NEU-induced checkpoint acti-
vation is similar to a previous study where IR-induced
damage resulted in an ATM–to–ATR switch via single-
stranded intermediates [32]. The absence of cross talk be-
tween the two signalling modules was ruled out by using
ATM and ATR kinase inhibitors, KU 55933 and VE 821
respectively.
It has been previously reported that damage caused
by DNA alkylating agents is recognized and repaired
by the mismatch repair pathway, which includes the
MutSα complex comprising of Msh2 and Msh6 pro-
teins [10,17,29,30]. A number of downstream targets
including Chk1, Chk2, p53 and CDC25A have shown
to be activated in an mismatch repair-dependent manner
[17,44], thereby positioning mismatch repair proteins at a
level above ATR kinase. We observed activation of Chk1
and Chk2 kinases, after individual knockdown of Msh6
or Msh2 in HeLa cells post 10 mM NEU damage. Inter-
estingly, knock down of Msh2 also led to a decrease in
Msh6 expression in the cells and vice versa. This is cor-
roborative with a previous study where the expression of
both proteins was required to maintain a steady-state
regulation of the mismatch repair system [45]. Our ob-
servation was further confirmed when we observed phos-
phorylation of Chk1 and Chk2 following 2 hours of NEU
induced damage in mismatch repair-deficient cell lines,
namely HCT116 and DLD1. Overall, the checkpoint acti-
vation profile in mismatch repair deficient cell lines post
NEU damage was found to be similar to that of mismatch
repair proficient cells.
In order to test the hypothesis that cells in different
phases of the cell cycle could respond differently to the
DNA damaging agent, cells were synchronised at S and
G2/M phases. S-phase synchronised cells showed activa-
tion of Chk1 as soon as they were released from the
block, while phosphorylation of Chk2 was observed from
20 minutes. The immediate activation of Chk1 may be
speculated to be due to sensitivity of the cells to NEU
damage during the replication cycle. There is a higher
propensity of single-stranded regions being exposed dur-
ing this cell cycle phase and therefore immediate ac-
tivation of Chk1. ATM as well as Chk2 activation was
delayed since activation of this pathway requires DSBs or
changes in chromatin structure [46]. Interestingly, the
checkpoint activation profile was observed to be different
during G2/M synchrony where a complete abrogation of
Chk1 was observed while ATM and Chk2 activation was
observed at 30 minutes post release from G2/M block in
NEU drug. This may be speculated to be due to a higher
incidence of sister chromatid exchange (SCE) in cells
treated with NEU as has been previously observed by
Kaina and his colleagues [47] and therefore propensity
for increased DSBs to occur during that time. Another
reasoning could be the presence of abasic sites formed
following the removal of the NEU adduct formed on
DNA, giving rise to gaps which may be recognised as
DSBs which then leads to the activation of ATM-Chk2
kinases as has been observed in our data.
This study has shed light on some of the players of the
DNA damage surveillance pathway that are activated
when a prototypical SN1 type-ethylating agent, NEU,
causes insult to DNA. There is a good number of studies
on methylating agents and their possible mechanism of
action in cells as well as their effect on some of the cellular
pathways such as DNA repair. Most research articles have
addressed O6meG and repair by mismatch repair, but lit-
erature addressing O6EtG lesions and its repair is lacking.
Figure 6 Model depicting temporal activation of checkpoint
signalling cascade following NEU damage on cells. According to
the model, ATM-Chk2 pathway gets activated at 10 minutes post
NEU damage followed by activation of Chk1 signalling cascade
at 20 minutes.
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Further investigations are necessary to understand the
DNA repair pathways that may be involved in repairing
the lesions induced by incorporation of an ethyl group to
DNA as well as any other sensor protein complex that may
first detect the mis-incorporation and then signal to the
apical checkpoint kinases. Although it has been reported
that DNA alkylating agents do not directly form DSBs, but
are formed after processing of lesions induced by the alkyl-
ating agent, our study provides evidence that on addition
of NEU, the ATM and Chk2 pathway is activated, as early
as 10 minutes. This is in contrast to earlier published work
where γH2AX foci formation was detected after 24 hours
[46]. Therefore, it will be interesting to investigate how
NEU alkylation damage is able to convert to a DSB lesion
that is capable of activating the DSB response pathway
within a short interval of time.
NEU is known to cause point mutations which ultim-
ately lead to the formation of mammary tumours in
rat models. NEU has been shown to induce neoplastic
transformation in vitro of rat mammary epithelial cell
[48]. In vitro studies have also shown NEU to act as an
active rat mammary gland genotoxic carcinogen [4,49].
During the process of neoplastic transformation, one of
the earliest stages of invasion is epithelial to mesenchy-
mal transition (EMT) wherein the epithelial cells acquire
mesenchymal characteristic so as to invade the surround-
ing extracellular matrix and migrate towards distant or-
gans [50,51]. EMT is characterised by loss of polarity of
the epithelial cells, appearance of mesenchymal markers
(upregulation of vimentin, fibronectin, N-cadherin) and
down regulation of the epithelial markers (E-cadherin,
occludins, cytokeratin 19, claudins) [52,53]. During EMT,
β-catenin which is membranous has been found to relo-
calise in the cytoplasm and/or nucleus [54]. Immortalised
breast epithelial cells (MCF10A) when treated with NEU
showed upregulation of vimentin. There was marginal
loss of E-cadherin following treatment, and complete loss
at 5 mM NEU treatment. NEU treatment at all doses also
led to disruption of polarity of cells in the acini, overall
giving rise to an EMT-like phenotype. Thus, it may be
speculated that NEU may play a role in causing trans-
formation in breast acini grown as 3D cultures.
Conclusions
In conclusion, our study reports two novel findings.
First, NEU causes DNA lesions within 2 hours of admin-
istration that causes the activation of checkpoint signal-
ling kinases, Chk1 and Chk2 in a temporal manner. This
activation does not depend upon the mismatch repair
complex and is cell cycle phase-dependent. The second
finding is that NEU can cause disruption of polarity in
cells forming the breast acini grown in 3D as well as
upregulate vimentin, thereby leading to transformation
in vitro. Therefore, NEU can potentially be used as an
agent to induce such a phenotype. This strategy will not
only permit the study of novel genes that are required
for normal mammary development but also shed light
on genes that get disrupted in breast cancer.
Additional files
Additional file 1: Figure S1. Checkpoint activation in MCF7 and HeLa
cells post NEU damage. (A) and (B) MCF7 and HeLa cells respectively
were treated with increasing NEU concentrations ranging from 0.2 mM
to 18 mM for 2 hours. Percent viability was determined for each NEU
dose by normalising corresponding absorbance at 570 nm with respect
to that of untreated cells. (C) HeLa cells were treated with 0, 2, 6 and
10 mM NEU for 2 hours and lysates were analysed for activation of
checkpoint proteins by immunoblotting. (D) HeLa cells were treated with
0, 0.3, 0.6, 1.2 and 1.8 mM NEU for 2 hours and lysates were analysed for
activation of checkpoint proteins by immunoblotting. (E) MCF7 cells
were treated with 10 mM NEU for 1 hour, fixed and analysed for γH2AX
foci formation by immunostaining. DMSO was used as negative control
and 200 ng/ml neocarzinostatin (NCS), an IR mimetic drug, was used as
positive control. Scale bar: 20 μM.
Additional file 2: Figure S2. NEU induced formation of DSBs and SSBs
in MCF7 cells. DNA damage in NEU treated MCF7 cells were measured
using comet assay. Cells treated with 10 mM NEU for two hours were
subjected to (A) neutral comet assay and (B) alkaline comet assay.
(A and B) Representative images of ethidium bromide stained control
cells, showing intact super coiled DNA (left) and treated cells showing
damaged DNA migrating out of the cell (right). (C and D) Cells treated
with 10 mM NEU at different time points were subjected to neutral
comet assay and alkaline comet assay. Representative images of ethidium
bromide stained control cells showing intact super coiled DNA and
treated cells at (C) 10, 30 and 60 minutes for neutral comet and (D) 10,
20, 30 and 60 minutes for alkaline comet showing damaged DNA
migrating out of the cell.Scale bar: 50 μM.
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